SPRY
ARS Pharmaceuticals, IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$778.49M
P/E Ratio
—
EPS
$-1.74
Beta
0.93
52W High
$18.90
52W Low
$6.66
50-Day MA
$8.46
200-Day MA
$10.67
Dividend Yield
—
Profit Margin
-203.30%
Forward P/E
—
PEG Ratio
—
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $84.28M |
| Gross Profit (TTM) | $50.67M |
| EBITDA | $-178.08M |
| Operating Margin | -147.60% |
| Return on Equity | -92.30% |
| Return on Assets | -33.00% |
| Revenue/Share (TTM) | $0.85 |
| Book Value | $1.15 |
| Price-to-Book | 6.90 |
| Price-to-Sales (TTM) | 9.24 |
| EV/Revenue | 7.59 |
| EV/EBITDA | -9.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.60% |
| Shares Outstanding | $99.30M |
| Float | $41.04M |
| % Insiders | 16.75% |
| % Institutions | 94.40% |
Historical Volatility
HV 10-Day
50.09%
HV 20-Day
39.87%
HV 30-Day
54.73%
HV 60-Day
50.69%
HV Rank
34.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($26.71 target)
6
BuyData last updated: 4/30/2026